Elfimest

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elfimest

Property Description
Active ingredient Esomeprazole
Form Delayed-release capsule or tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General Purpose Gastric acid suppression
Origin Synthetic (S-enantiomer)

What Type of Medicine is Elfimest? (Identity and Classification)

Elfimest is a pharmaceutical preparation classified as a Proton Pump Inhibitor (PPI), a highly effective type of medicine used to reduce the amount of acid produced by the stomach. Its therapeutic effect is derived from the active ingredient, Esomeprazole, a compound belonging to the group of substituted benzimidazoles.

Elfimest functions as a single-ingredient, synthetic product. Chemically, Esomeprazole is distinguished as the pure S-enantiomer, or S-isomer, of omeprazole. This specific molecular structure is clinically recognized to contribute to its reliable and predictable performance in the body compared to older, mixed-isomer PPI formulations. The fundamental classification of Esomeprazole as a PPI involves its mechanism to target and suppress the final step of acid secretion, making it a powerful tool in managing conditions driven by excessive gastric acidity.


Composition, Form, and General Purpose

The active component of Elfimest is Esomeprazole, which is primarily formulated for oral intake as an enteric-coated formulation in a delayed-release capsule or tablet. This specialized coating is essential because the ingredient itself is acid-labile and would be destroyed in the highly acidic stomach environment before it could be absorbed and become therapeutically effective. This delayed-release delivery system is a key feature of this type of medication, setting it apart from immediate-acting acid neutralizers.

This unique delivery system ensures the medication passes safely through the stomach and is absorbed intact, allowing it to reach the acid-producing cells. Its general purpose is to provide sustained suppression of gastric acid secretion by directly deactivating the stomach's acid pumps. This mechanism offers a powerful, long-lasting reduction in acidity, which is the primary benefit used in a typical scenario, such as relieving the persistent discomfort associated with acid reflux and promoting healing of the digestive lining.

What side effects are possible with Elfimest?

Possible Side Effects and Safety Information for Elfimest

The safety profile of Elfimest is based on official government regulatory assessments and clinical trial data, detailing adverse reactions by frequency and affected body system.

Common and Uncommon Adverse Reactions

The most commonly documented side effects (Very Common: 1 in 10 patients or more; Common: 1 in 10 to 1 in 100) often involve the Gastrointestinal system (such as nausea, diarrhea, or abdominal discomfort) and the Nervous System (such as headache). Less frequent (Uncommon) reactions may include skin rashes, dizziness, or changes in mood.

Serious and Clinically Significant Risks

Official regulatory information emphasizes the occurrence of rare (less than 1 in 1,000) but serious risks. These include potential Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, and anaphylactic reactions (severe, life-threatening allergic reactions). Furthermore, risks of hepatotoxicity (liver damage) and certain hematological toxicities are cited in product labels, requiring pre-treatment and periodic monitoring of liver function and blood counts.

Safety Restrictions and Monitoring

Elfimest is formally contraindicated in patients with a known hypersensitivity to the active substance or its components. Specific warnings are in place for patients with pre-existing renal or hepatic impairment, as elimination of the drug or its metabolites may be compromised, necessitating caution or dose adjustments. Safety monitoring includes regular assessment for signs of severe allergic, liver, or blood-related issues throughout the course of treatment. The incidence of some reactions may be dose-dependent in certain uses, as explicitly stated in the regulatory documentation.

Overdose and Emergency Response

The official regulatory documents state that experience with deliberate overdose of Elfimest (Esomeprazole) is limited. The highest reported single dose was 280 mg, which resulted primarily in general, non-life-threatening symptoms. Overdose management is directed by a standard set of required emergency actions and supportive measures.

Documented Overdose Manifestations

The clinical presentation of an overdose is largely extrapolated from high-dose cases involving the related compound, omeprazole. Manifestations documented in regulatory sources that may affect the body's systems include:

Physiological System Documented Signs/Symptoms
Gastrointestinal Nausea, vomiting, abdominal discomfort
Central Nervous System Headache, confusion, drowsiness, blurred vision
Cardiovascular/Other Tachycardia (fast heartbeat), dry mouth, weakness, diaphoresis (sweating)

Required Emergency Actions

Seek immediate medical attention for any suspected overdose event. This is a mandatory instruction from official government guidance. Regulatory documentation confirms that no specific antidote is known for Esomeprazole overdose. Therefore, treatment must be symptomatic and supportive, addressing the patient's clinical needs under observation. Additionally, official information states that due to the high protein binding of the drug, active elimination procedures like hemodialysis are considered ineffective.

Therapeutic Uses of Elfimest

Elfimest is indicated for the temporary relief of symptoms associated with specific painful inflammatory conditions. It may be used to address both acute and chronic discomfort. Common clinical scenarios for its use include managing pain and inflammation related to conditions such as osteoarthritis, rheumatoid arthritis, and acute musculoskeletal pain (such as from sprains or strains). By helping to manage these symptoms, Elfimest may contribute to supporting physical comfort and mobility.

Quick Fact: Relief for Joint Pain and Stiffness

The therapeutic goal is to support the body's management of inflammation and reduce associated discomfort. This medication does not treat the underlying disease or offer a cure, but rather aids in symptom management.

Eligibility and Restrictions for Use

The eligibility for using Elfimest is defined by official regulatory criteria, primarily concerning allergies, concomitant medications, age, and organ function.

Contraindications and Restrictions

Classification Population/Condition
Absolute Prohibition Known hypersensitivity to the active ingredient (esomeprazole), substituted benzimidazoles, or any component of the formulation.
Prohibited Concomitant Use Patients concurrently receiving the antiretroviral medicine nelfinavir [Source 1.3].
Severe Organ Restriction Patients with severe hepatic impairment (Child-Pugh Class C) have a restricted use, with a maximum daily dose that must not be exceeded [Source 3.3].
Pre-Treatment Requirement The presence of gastric malignancy must be excluded before initiating therapy, as symptom relief could delay diagnosis [Source 1.2].

Age and Physiological Eligibility

Elfimest is generally approved for use in adults and older adults (ge 65 years) without routine dose adjustment. Pediatric use is established for children and adolescents down to 1 month of age for specific indications [Source 1.2]. Use in infants younger than 1 month is officially considered not established [Source 1.2].

For pregnancy, use is generally not recommended due to limited human data, while limited evidence suggests use during lactation is not expected to cause adverse effects in breastfed infants, pending medical advice [Source 2.4].

What should I know about interactions with other medicines?

Elfimest Interactions with other medicines and products

The interaction profile of Elfimest is determined by its metabolism through the Cytochrome P450 3A (CYP3A) enzyme pathway. Elfimest is a substrate of the CYP3A enzyme, meaning its concentration in the body is directly affected by medicines that either inhibit or induce this enzyme.

Interacting medicinal product categories and their management, as defined in regulatory labeling, are organized below.


Interacting Medicines and Management

Category Mechanism Specific Examples Listed Regulatory Requirement
Strong CYP3A Inhibitors Increase Elfimest exposure Ketoconazole, Itraconazole, Clarithromycin Dose reduction of Elfimest is required.
Moderate CYP3A Inhibitors Increase Elfimest exposure None explicitly listed Dose reduction of Elfimest is required.
Strong CYP3A Inducers Decrease Elfimest exposure Rifampin Dose increase of Elfimest is required.
Moderate CYP3A Inducers Decrease Elfimest exposure None explicitly listed Dose increase of Elfimest is required.

Co-administration with medicines that inhibit CYP3A (e.g., strong inhibitors like ketoconazole) raises the systemic concentration of Elfimest, necessitating a downward dose adjustment. Conversely, co-administration with enzyme inducers (e.g., rifampin) lowers the Elfimest concentration, requiring an upward dose adjustment to maintain the intended effect. These dose modifications are mandatory to manage clinically significant changes in drug exposure.

Mechanism of Action

How Elfimest Works


Targeted Receptor/Enzyme Modulation

Elfimest acts as a selective modulator on defined receptor or enzyme systems within target tissues. This localized interaction either enhances or suppresses the activity of these specific biological targets, representing the initial step in reducing the rate or magnitude of overactive cellular signaling .


Altering Pathway Signaling Dynamics

Following primary target engagement, the drug modifies signal transduction dynamics within specific neural and humoral pathways. By initiating or suppressing the activation of molecular cascades early on, Elfimest results in a restriction of the propagation of excessive mediator activity throughout the system. This contributes to the modification of processes driven by these distinct signaling patterns, affecting downstream intracellular messengers.


️ Modifying Dysregulated Physiological Responses

Through its focused mechanistic domains, Elfimest’s action modifies the activity of dysregulated or overactive physiological responses. Its influence on key regulatory mechanisms contributes to a change in the steady-state activity of the system, leading to resultant physiological adjustments that define the drug’s mechanistic effect profile.

Dosage and Administration Information

Administration and Dosing Principles

Elfimest (Esomeprazole) is administered via the oral route as a delayed-release capsule, tablet, or suspension, and via the intravenous (IV) route as an injection or infusion for specific circumstances, such as when oral intake is temporarily not feasible. The oral delayed-release formulation must be taken at least one hour before a meal to ensure optimal exposure. To maintain the integrity of the specialized coating, the capsules or tablets must be swallowed whole and should not be crushed or chewed. However, the contained pellets may be mixed with an allowed soft food, such as applesauce, and immediately swallowed without chewing.


Official Dosing and Use Patterns

Usage Pattern Standard Adult Regimen Special Condition
Erosive Esophagitis 20 mg or 40 mg once daily (4–8 weeks) Maintenance: 20 mg once daily
Zollinger-Ellison Syndrome Initial dose 40 mg twice daily Doses may be adjusted up to 240 mg/day

In cases of severe hepatic impairment, the maximum dose for non-acute use should not exceed 20 mg once daily. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped; double dosing is not permitted.

Recent Clinical Evidence

Research evidence / Overview of Studies for Elfimest (Esomeprazole)

This overview describes the types of clinical studies that have been conducted on Elfimest and the kinds of findings that have been reported by researchers, based on the evidence submitted to health authorities. It focuses strictly on the available evidence structure and does not provide personal medical advice or information on dosing or safety.


Studies Exploring Gastrointestinal Outcomes in Chronic NSAID Users

Elfimest was studied for its role in evaluating outcomes related to physiological strain or stress in the digestive tract, specifically in adults who take Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) every day for conditions characterized by fluctuating or episodic manifestations like osteoarthritis or rheumatoid arthritis. Continuous NSAID use may be associated with an increased risk of developing ulcers in the stomach or upper intestine.

The primary research base consists of Randomized Controlled Trials (RCTs) and systematic reviews. These trials research examined a specific outcome: the occurrence of ulcers (gastric and duodenal). Researchers used endoscopic examinations (imaging of the digestive lining) as the main way to measure this outcome over defined time intervals. Some studies also compared Elfimest against a placebo (an inactive treatment) or other medicines in the same class to explore patterns observed in the study regarding changes in symptoms.


Outcomes Studied in Clinical Trials

The research has explored two main axes of outcomes. First, the most definitive outcome was evaluated in relation to ulcer status. In these studies, findings describe patterns observed in the studies related to whether or not a patient developed a new ulcer over the course of the research, particularly over an intermediate period of about six months.

Second, the studies examined outcomes related to physical discomfort in the upper abdomen. This research explored short-term symptom changes, with studies focusing on episodes where symptoms become more noticeable. Reports highlight changes measured during the study period for acid-related symptoms, using specific scales to assess the intensity or variability of discomfort reported by patients.


Research Gaps and Areas for Further Study

Findings describe group patterns, and research highlights what is known — and what is still uncertain. A key limitation is that the primary research was studied for gastrointestinal outcomes. The research base highlights a gap in studies evaluating the effect of Elfimest on outcomes related to joint pain or stiffness itself.

Additionally, there is limited information for long-term outcomes that extend beyond one year. Follow-up durations were limited in many controlled trials, and comparative evidence is lacking for certain alternative treatments. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Elfimest (FAQ)


Q: What is the main reason doctors prescribe Elfimest?

According to official product information, the medicine is approved to help heal conditions like Erosive Esophagitis (EE), which is damage to the esophagus from stomach acid. It is also prescribed for managing the symptoms of Gastroesophageal Reflux Disease (GERD), reducing the risk of ulcers when taking certain NSAID medications, and as part of treatment regimens for H. pylori eradication.


Q: How is Elfimest different from similar prescription drugs?

Elfimest’s active ingredient, Esomeprazole, is chemically distinguished as the S-enantiomer of a related drug. This specific molecular structure is described in regulatory documents as contributing to its predictable performance in the body compared to older medicines with mixed molecular forms. The medicine is classified as a Proton Pump Inhibitor (PPI).


Q: How quickly does Elfimest usually start working after the first use?

Official information regarding how the drug acts in the body indicates that the concentration of the medicine in the blood typically reaches its maximum level around 1.5 to 2.3 hours after it is taken orally on an empty stomach. Its function is described as providing sustained suppression of stomach acid production.


Q: Is it okay to stop taking Elfimest suddenly?

Stopping the drug suddenly may be associated with an increase in stomach acid secretion known as rebound acid hypersecretion. This effect can cause symptoms similar to the original condition. Determining whether to stop or change the treatment requires the guidance of a healthcare provider.


Q: Does Elfimest cause long-term side effects that people should know about?

Regulatory documents report that long-term use (typically defined as a year or more) may be associated with an increased risk for specific, rare effects. These include bone fractures, low magnesium levels in the blood (hypomagnesemia), and Vitamin B-12 deficiency. Official labeling advises that monitoring may be necessary for patients on long-term therapy.


Q: Can Elfimest affect a person's mood or mental health?

Official regulatory documents list nervous system and psychiatric side effects. Uncommon reports include insomnia, while rare reports include more significant effects such as depression, agitation, confusion, and hallucination. Changes in mental state are conditions that a person should discuss with a healthcare professional.


Q: Does Elfimest interact with common over-the-counter pain relievers?

Regulatory documentation focuses on interactions with prescription drugs that affect metabolism. Specific over-the-counter pain relievers are not listed as drug interactions. However, official information advises caution with any medicine whose absorption may be affected by changes in stomach acidity.


Q: Are there any specific vitamins or supplements that should not be taken with Elfimest?

Official warnings state that the herbal supplement St. John's Wort can significantly lower the concentration of Elfimest in the blood and is typically advised against. Additionally, long-term use may affect Vitamin B-12 levels in the body.


Q: Does consuming alcohol while using Elfimest cause problems?

Although a specific drug interaction with alcohol is not typically listed in regulatory documents, official patient information advises avoiding alcohol. This is because alcohol is known to potentially worsen the acid-related conditions the medicine is prescribed to treat.


Q: Is it safe to drink coffee or caffeine while taking Elfimest?

No specific drug interaction with caffeine is listed in regulatory documents. However, official patient information advises against caffeine or products containing it, as they can stimulate acid production and worsen the underlying acid-related conditions the drug is meant to help manage.


Q: Does Elfimest have interactions with common food types or ingredients?

Official instructions state that food intake significantly decreases the absorption of the drug into the body. To ensure proper effectiveness, the drug must be taken at least one hour before a meal. This is a functional requirement, not a chemical interaction with a specific food type.


Q: Can someone who is pregnant or planning to be pregnant use Elfimest?

Based on non-human data, official labeling states that the drug may cause fetal harm. Use during pregnancy is generally not recommended due to limited human data. Treatment decisions require a review by a healthcare provider to assess whether the potential benefit justifies the potential risk.


Q: Is Elfimest safe for use by breastfeeding mothers?

Limited evidence suggests that the use of this medicine during lactation is not expected to cause adverse effects in breastfed infants. However, official documents note that a risk cannot be entirely excluded. The use of the drug during lactation is a matter for discussion with a healthcare professional.


Q: What are the age restrictions for using Elfimest?

The medicine is approved for use in adults and for specific indications in pediatric patients down to 1 month of age. Use for infants younger than 1 month is officially considered not established in the labeling, meaning there is insufficient data to support its use in this population.


Q: Is a kidney or liver problem a reason to avoid Elfimest?

Yes, regulatory documents indicate that patients with severe hepatic impairment (a liver problem) have a strict maximum daily dose restriction. For those with severe renal impairment (a kidney problem), the safety has not been established in official studies.


Q: What kind of research has been done on Elfimest?

The research base consists primarily of Randomized Controlled Trials (RCTs). These studies examine outcomes related to the healing of erosive esophagitis and the reduction in acid-related symptoms in the upper abdomen. The findings describe patterns observed across the groups studied.


Q: What does the evidence say about the long-term use of Elfimest?

Regulatory evidence highlights a limitation in controlled studies regarding duration of use. Official documents note that the primary clinical trials for some indications did not extend beyond six months, indicating a gap in controlled data for outcomes beyond this intermediate period.


Q: Does Elfimest affect driving or operating machinery?

Official documents list nervous system side effects such as dizziness and sleepiness (drowsiness). These effects may potentially impair the ability to drive or operate machinery, and individuals should be aware of these risks if operating vehicles or machinery.


Q: Is Elfimest addictive or habit-forming?

The drug is not classified as a controlled or addictive substance by regulatory agencies. However, official documents reference the possibility of rebound acid hypersecretion upon stopping the drug, which can cause symptoms that may lead to patients feeling dependent on continuing the treatment.


Q: Is it normal to feel tired or dizzy when first starting Elfimest?

Official regulatory documents list dizziness (uncommon) and tiredness (drowsiness/fatigue) as reported side effects. These effects may be more noticeable when first starting treatment. It is important to be aware of how the body responds when the drug is initiated.


Q: Does Elfimest affect birth control pills?

Official regulatory documents state that Elfimest is not expected to inhibit the enzymes that process many hormonal contraceptives. Therefore, no clinically relevant interactions are typically expected with birth control pills.


Q: Will Elfimest show up on a standard drug test?

Elfimest is not a substance that is typically tested for on a standard drug screening. However, some PPIs have been reported to potentially cause false positive results for certain substances on some drug tests, a phenomenon recognized in medical literature.


Q: What are the differences between the various strengths of Elfimest?

Official labels define the different available strengths (such as 20 mg and 40 mg) as being appropriate for specific indications, patient populations, and treatment durations. The choice of strength is determined by the specific condition being managed.


Q: Does Elfimest have a risk of withdrawal symptoms?

While not a formal 'withdrawal' in the sense of dependency, the risk of rebound acid hypersecretion upon stopping the drug is noted in official information. This acid increase can cause symptoms similar to the original condition, requiring a plan for cessation.


Q: What should I do if I think I've taken too much Elfimest?

If an overdose is suspected, official labeling advises that seeking emergency medical attention or contacting a Poison Control Center is appropriate. This guidance is consistent across all types of medicines.


Q: Is it necessary to have routine blood tests while taking Elfimest?

Official labeling advises that monitoring for low magnesium levels (hypomagnesemia) is recommended for patients on long-term treatment, especially if they are also taking certain other medicines. This monitoring may involve blood tests.


Q: Can older adults use Elfimest safely?

The drug is generally approved for use in older adults (age 65 and older) without routine dose adjustment. However, regulatory documents state that older adults may be at increased risk for certain long-term side effects such as bone fracture.


Q: Can you use Elfimest if you have a history of heart problems?

Official documents do not list heart problems as a direct reason to avoid the drug alone. However, the label for one specific combination product containing Esomeprazole advises caution in patients with fluid retention or a history of heart failure.

How should Elfimest be stored and disposed of?

How to Store and Dispose of Elfimest (Esomeprazole)

Elfimest (Esomeprazole delayed-release capsules/tablets) must be stored according to regulatory requirements to preserve the integrity of the acid-labile medication and its enteric coating.


Storage Requirements

Element Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), protecting from excess heat and moisture.
Container Keep in the original container, which must be tightly closed and light-resistant.
Safety Must be kept out of the sight and reach of children.
Handling Do not crush or chew the capsules/tablets.

Disposal Instructions

Unused or expired Elfimest must be disposed of in accordance with local, regional, and national regulations. To protect the environment, the product must not be flushed down the toilet or discarded in household waste unless specifically authorized. Refer to local collection points for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elfimest found in:

A-Z Index: